Download PDF
Thromb Haemost 1997; 77(04): 650-655
DOI: 10.1055/s-0038-1656028
Clinical Studies
Schattauer GmbH Stuttgart

Pharmacokinetics of Recombinant Hirudin in Hemodialyzed End-stage Renal Failure Patients

R Vanholder
1   The Nephrology Department, Division of Internal Medicine, University Hospital, Gent, Belgium
,
A Camez
2   The Laboratoires Hoechst, Medical Department, Puteaux, France
,
N Veys
1   The Nephrology Department, Division of Internal Medicine, University Hospital, Gent, Belgium
,
A Van Loo
1   The Nephrology Department, Division of Internal Medicine, University Hospital, Gent, Belgium
,
A M Dhondt
1   The Nephrology Department, Division of Internal Medicine, University Hospital, Gent, Belgium
,
S Ringoir
1   The Nephrology Department, Division of Internal Medicine, University Hospital, Gent, Belgium
› Author Affiliations
Further Information

Publication History

Received 05 March 1996

Accepted after revision 19 December 1996

Publication Date:
11 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Recently, hirudin was used for the first time as an anticoagulant during hemodialysis in men. Pharmacokinetic data of this compound in end-stage renal failure are however not available. In this study, the pharmacokinetics of recombinant hirudin (HBW 023) was evaluated in hemodialysis-treated end-stage renal failure patients. HBW 023 was administered as a bolus at the start of a single dialysis (0.02 to 0.08 mg/kg) in 20 patients, and plasma hirudin levels were followed during this and the 5 following dialyses, without additional hirudin administration. The initial dialysis (HDj) was performed with a low flux polysulfone dialyzer; the following dialyses (up to HD6) with a high flux polysulfone dialyzer and regular heparin. Hirudin levels averaged 504.0 ± 214.0 and 527.7 ± 217.1 ng/ml in the middle and at the end of HDj, and then gradually decreased to 15.2 ± 15.2 ng/ml at the end of HD6. Pharmacokinetic data were compared to those obtained in healthy controls (n = 5), receiving the same dose, and reaching the same peak hirudin level. Hirudin half-life was >30 times longer in hemodialysis patients (51.8 ± 15.6 vs. 1.7 ± 1.5 h, p <0.001), whereas area under the curve was >60 times higher (34,669 ± 14,898 vs. 545 ± 205 ng/ml X h, p <0.001). Distribution volume was lower in hemodialysis patients (11.0 ± 3.1 vs. 14.1 ± 2.0 1, p <0.05). Hirudin disappearance rate was the same during high flux polysulfone dialysis as during interdialytic periods. Hirudin removal was markedly higher in those patients still maintaining some residual renal function and parameters of hirudin removal were significantly correlated to residual creatinine clearance. It is concluded that hirudin removal from the body is markedly depressed in hemodialyzed end-stage renal failure patients and that even minor residual renal function may increase this removal rate.

 

  • References

  • 1 Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW. The structure of a complex of recombinant hirudin and human a-thrombin. Science 1990; 249: 277-280
    CrossrefPubMedGoogle Scholar
  • 2 Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Haemost 1991; 66: 141-152
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Anonymous. Editorial. Hirudins: return of the leach?. Lancet 1992; 340: 579-580
    CrossrefPubMedGoogle Scholar
  • 4 Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574
    CrossrefPubMedGoogle Scholar
  • 5 Freedman MD. Pharmacodynamics, clinical indications, and adverse effects of heparin. J Clin Pharmacol 1992; 32: 584-596
    CrossrefPubMedGoogle Scholar
  • 6 Hirsh J, Dalen JE, Deykin D, Poller L. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chestl 1992; 102: S337-S351
    PubMedGoogle Scholar
  • 7 Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lemer RG, Hall J, Sparling T, Brettell HR, Norton J, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenblum D, Brant R. Subcutaneous lowmolecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982
    CrossrefPubMedGoogle Scholar
  • 8 Neuhaus KL, vEssen R, Tebbe U, Vogt A, Michels HR, Appel KF, Jessel A, Zeymer U. Hirudin and thrombolysis with front-loaded alteplase in acute myocardial infarction. Results of a pilot study. J Am Coll Cardiol 1993; 21 (Suppl. 02) 418A (abstract).
    PubMedGoogle Scholar
  • 9 Cannon CP, McCabe CH, Henry DT, Rogers WJ, Schweiger M, Gibson RS, Anderson JL, Williams DO, Braunwald E. Hirudin reduces reocclusion compared to heparin following thrombolysis in acute myocardial infarction: Results of the TIMI5 study. J Am Coll Cardiol 1993; 21 (Suppl. 02) 136A (abstract).
    PubMedGoogle Scholar
  • 10 Sharaf BL, Miele N, Ferreira P, McKendall GR, Williams DO. Culprit lesion changes in acute myocardial infarction: a TIMI 5 comparison of patients treated with t-PA and either heparin or hirudin. J Am Coll Cardiol 1993; 21 (Suppl. 02) 419A (abstract).
    CrossrefPubMedGoogle Scholar
  • 11 Agnelli G, Renga C, Weitz JI, Nenci GG, Hirsh J. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Blood 1992; 80: 960-965
    PubMedGoogle Scholar
  • 12 Bucha E, Markwardt F, Nowak G. Hirudin in haemodialysis. Thromb Res 1990; 60: 445-455
    CrossrefPubMedGoogle Scholar
  • 13 Nowak G, Bucha E, Gööck Th, Thieler H, Markwardt F. Pharmacology of r-hirudin in renal impairment. Thromb Res 1992; 66: 707-715
    CrossrefPubMedGoogle Scholar
  • 14 Vanholder RC, Camez AA, Veys NM, Soria J, Mirshahi M, Soria C, Ringoir S. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int 1994; 45: 1754-1759
    CrossrefPubMedGoogle Scholar
  • 15 Griessbach U, Stürzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate. Thromb Res 1985; 37: 347-350
    CrossrefPubMedGoogle Scholar
  • 16 Groetsch H, Berscheid G, Hropot M, Ben YoussefR. Interference of heparin and analogues with hirudin in the chromogenic thrombin substrate assay. Thromb Res 1991; 64: 285-290
    CrossrefPubMedGoogle Scholar
  • 17 Meyer BH, Luus HG, Müller FO, Badenhorst PN, Röthig HJ. The pharmacology of recombinant hirudin, a new anticoagulant. S Afr Med J 1990; 78: 268-270
    PubMedGoogle Scholar
  • 18 Zoldhelyi P, Webster MWI, Fuster V, Grill DE, Gaspar D, Edwards SJ, Cabot CF, Chesebro JH. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 1993; 88: 2015-2022
    CrossrefPubMedGoogle Scholar
  • 19 Grötsch H, Hropot M. Degradation of rDNA hirudin and a-human thrombin hirudin complex in liver and kidney homogenates from rat. Thromb Res 1991; 64: 763-767
    CrossrefPubMedGoogle Scholar
  • 20 Vanholder R, Hsu C, Ringoir S. Biochemical definition of the uremic syndrome and possible therapeutic implications. Artif Organs 1993; 17: 234-239
    PubMedGoogle Scholar
  • 21 Hsu CH, Patel SR, Vanholder R. Mechanism of decreased intestinal calcitriol receptor concentration in renal failure. Am J Physiol 1993; 264: F662-F669
    PubMedGoogle Scholar
  • 22 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 01-17
    PubMedGoogle Scholar
  • 23 Vitoux JF, Mathieu JF, Roncato M, Fiessinger JN, Aiach M. Heparin associated thrombocytopenia: treatment with low molecular weight heparin. Thromb Haemost 1986; 55: 37-39
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Horellou MH, Conard J, Lecrubier C, Samama M, Roque-D’Orbcastel O, de FenoylO, Di MariaG, Bemadou A. Persistent heparin induced thrombocytopenia despite therapy with low molecular weight heparin. Thromb Haemost 1984; 51: 134 (letter).
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Vanholder R, De SmetR, Hsu C, Vogeleere P, Ringoir S. Uremic toxicity: the middle molecule hypothesis revisited. Sem Nephrol 1994; 14: 205-218
    PubMedGoogle Scholar